Allurion Technologies (ALURD) Liabilities and Shareholders Equity (2022 - 2026)
Allurion Technologies' (ALURD) quarterly Liabilities and Shareholders Equity came in at $14.0 million in Q1 2026, down 63.57% YoY from $38.4 million in Q1 2025, and down 11.27% on a QoQ basis from $15.8 million in Q4 2025.
Allurion Technologies (ALURD) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends
Allurion Technologies (ALURD) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $14.0 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 63.57% year-over-year to $14.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.1 million (down 54.84% YoY) and the FY2025 annual result came in at $15.8 million, down 51.93% from the prior year.
- Liabilities and Shareholders Equity declined to $14.0 million in Q1 2026, from $15.8 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $120.7 million in Q3 2023 to a low of $14.0 million in Q1 2026.
- A 5-year average of $46.2 million and a median of $46.6 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 39.6% — and 2025, when it tumbled 64.22%.
- Tracing ALURD's Liabilities and Shareholders Equity over 5 years: stood at $51.4 million in 2022, then jumped by 39.6% to $71.7 million in 2023, then tumbled by 54.24% to $32.8 million in 2024, then slumped by 51.93% to $15.8 million in 2025, then slipped by 11.27% to $14.0 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $14.0 million (Q1 2026), $15.8 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Allurion Technologies | 49.18 Mn | 44.13 Mn | 1.23 Mn | 14.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.00 Mn |
| Dec 31, 2025 | 15.77 Mn |
| Sep 30, 2025 | 18.14 Mn |
| Jun 30, 2025 | 28.17 Mn |
| Mar 31, 2025 | 38.41 Mn |
| Dec 31, 2024 | 32.81 Mn |
| Sep 30, 2024 | 50.70 Mn |
| Jun 30, 2024 | 46.55 Mn |
| Mar 31, 2024 | 59.99 Mn |
| Dec 31, 2023 | 71.71 Mn |
| Sep 30, 2023 | 120.69 Mn |
| Jun 30, 2023 | 52.15 Mn |
| Dec 31, 2022 | 51.37 Mn |